See every side of every news story
Published loading...Updated

Coya reports progress of first-in-class Treg-derived exosome program - BioTuesdays

Summary by biotuesdays.com
Coya Therapeutics (NASDAQ:COYA) announced a status update of its investigational regulatory T cell-derived exosome—Treg exosomes—platform for the treatment of systemic and neurodegenerative diseases driven by chronic inflammation. According to Coya, sustained inflammatory responses caused by dysfunctional immune regulation, is characteristic of serious autoimmune and neurodegenerative diseases. In a statement, Fred Grossman, DO, CMO of Coya, com…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

biotuesdays.com broke the news in on Wednesday, March 26, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.